Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.33 |
| ▸ | LOX | P28300 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620049 | 0.79 | EGLN2 (0.31) | ALDH1A1EGLN2EGLN1EGLN3 | |
| SCHEMBL7768127 | 0.79 | EGLN2 (0.31) | ALDH1A1EGLN2EGLN1EGLN3 | |
| SCHEMBL1959957 | 0.79 | EGLN2 (0.31) | ALDH1A1EGLN2EGLN1EGLN3 | |
| SCHEMBL13563819 | 0.79 | EGLN2 (0.31) | ALDH1A1EGLN2EGLN1EGLN3 | |
| SCHEMBL8241659 | 0.79 | FDPS (0.37) | ALDH1A1EGLN2EGLN1EGLN3 | |
| SCHEMBL5751006 | 0.79 | SCD (0.34) | ALDH1A1EGLN2EGLN1EGLN3CYP2A6 | |
| SCHEMBL129946 | 0.79 | EGLN2 (0.31) | ALDH1A1EGLN2EGLN1EGLN3 | |
| Hydrochloric Acid SCHEMBL18641463 | 0.78 | SLC6A3 (0.44) | LOXL2LOXCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL10864494 | 0.77 | MAOB (0.33) | — | |
| SCHEMBL17263320 | 0.76 | SLC6A3 (0.34) | EGLN2EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4463452-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-110612300-B | Process for preparing hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| CN-104203928-A | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL IND LTD | 2014-12-10 | — | — | CN | disclosed |
| EP-0665222-B1 | Guanidine derivatives, their production and insecticides | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-5633375-A | NONTOXIC TO HUMNAS, ANIMALS, FISH | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-27 | — | — | US | disclosed |
| US-5489603-A | CONTAINING NITROGEN HETEROCYCLIC RINGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-06 | — | — | US | disclosed |
| EP-0493369-B1 | Guanidine derivatives, their production and insecticides | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-11-08 | — | — | EP | disclosed |
| EP-0665222-A1 | Guanidine derivatives, their production and insecticides | Takeda Chemical Industries, Ltd. (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0493369-A1 | Guanidine derivatives, their production and insecticides | Takeda Chemical Industries, Ltd. (JP) | 1992-07-01 | — | — | EP | disclosed |
| US-5034404-A | Nitroguanidines as insecticides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0376279-A2 | Guanidine derivatives, their production and insecticides | Takeda Chemical Industries, Ltd. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | ALDH1A1 4316/4885LOXL2 4411/4885LOX 4240/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | ALDH1A1 4316/4885LOXL2 4411/4885LOX 4240/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | ALDH1A1 4471/4885LOXL2 4418/4885LOX 4055/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | ALDH1A1 4471/4885LOXL2 4418/4885LOX 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.